JOHNSON INVESTMENT COUNSEL INC
Position in ARWR — Arrowhead Pharmaceuticals, Inc.
CIK 821197
Cincinnati, OH
Position in ARWR
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$326,040
+$75,240 QoQ
Shares Held
4,000
0.0% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#62
of 123 holders
Holding Since
Dec 2022
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ARWR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JOHNSON INVESTMENT COUNSEL INC holds $10,648,095 across 9 Biotechnology names. ARWR ranks #6 (3.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,360 | $3,655,932 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
37,016 | $2,897,242 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
9,802 | $2,361,987 | |
| 4 | INCY |
Incyte Corp
|
4,681 | $530,638 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
8,212 | $451,167 | |
| 6 | ARWR |
Arrowhead Pharmaceuticals, Inc.
This page
|
4,000 | $326,040 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
468 | $291,816 | |
| 8 | AVIR |
Atea Pharmaceuticals, Inc.
|
25,590 | $118,993 |
All Filings in ARWR
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $326,040 | 4,000 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $250,800 | 4,000 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $398,340 | 6,000 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $780,681 | 22,635 | Shares | Sole | 2025-11-06 | |
| 2022-12-31 | $202,800 | 5,000 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||